脊髓弥漫性中线H3K27变异型胶质瘤:系统综述
本系统综述纳入39项研究共279例经组织学确诊的脊髓弥漫性中线H3K27变异型胶质瘤患者,总结其临床特征、治疗与结局。患者平均年龄32岁,61%为男性,最常见的治疗为手术联合放化疗(31%)或仅手术(24%),替莫唑胺是最常用化疗药(81%)。平均随访21个月时13%存活,平均中位总生存24个月(范围13-40个月),中位无进展生存14个月;历史WHO 2或3级者平均中位总生存长于4级(32 vs 23个月,p=0.009)。
要点
- 脊髓弥漫性中线H3K27变异型胶质瘤总体预后差,但似乎优于颅内弥漫性中线胶质瘤。
- 历史WHO 2或3级者平均中位总生存32个月,长于4级的23个月(p=0.009)。
- 平均随访21个月时仅13%患者存活,中位无进展生存14个月。
核心结论
- 脊髓弥漫性中线H3K27变异型胶质瘤总体结局差,但似乎优于颅内弥漫性中线胶质瘤;基于历史分级系统报告的总生存差异,未来需进一步研究以明确该肿瘤是否代表预后不同的异质性群体。
研究设计与样本
- 系统综述,检索PubMed、Ovid EMBASE、Scopus和Web of Science自建库至2023年9月23日,纳入经组织学确诊的脊髓弥漫性中线H3K27变异型胶质瘤病例,共39项研究279例患者。
主要发现
- 患者61%为男性,平均年龄32岁;31%接受手术联合放疗和化疗,24%仅接受手术,38%为次全切除;替莫唑胺为最常用化疗药(81%);放疗平均剂量47 Gy,分23次。
- 平均随访21个月时13%患者存活;平均中位总生存24个月(范围13至40个月),中位无进展生存14个月。
- 历史WHO 2或3级者平均中位总生存32个月,长于4级的23个月(p=0.009)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To systematically review the clinical features, management, and outcomes of diffuse midline H3K27-altered gliomas of the spinal cord (DMG-SCs). METHODS: PubMed, Ovid EMBASE, Scopus, and Web of Science were searched from database inception to 23 September 2023 for histologically confirmed cases of DMG-SC. Patient demographics, tumor characteristics, management information, and survival outcomes were extracted and analyzed. RESULTS: A total of 279 patients from 39 studies were collected. Patients were mostly male (61%), with an average age of 32 years. Patients were treated with surgery, radiotherapy, and chemotherapy combined (31%) or surgery only (24%), and extent of resection was most often subtotal (38%). Temozolomide was the most common chemotherapeutic agent (81%). Radiation therapy was delivered with mean dose of 47 Gy in 23 fractions. At mean follow-up time of 21 months, 13% of patients were alive. Average median overall survival was 24 months (range of 13 to 40 months) with a median progression-free survival of 14 months. Historical WHO grades of 2 or 3 appeared to exhibit a longer average median overall survival time than that of grade 4 DMG-SCs (32 vs. 23 months, p = 0.009). CONCLUSIONS: Outcomes for DMG-SCs are poor overall but appear to be favorable compared to intracranial DMGs. Despite the recent WHO 2021 grade 4 classification for all DMGs, given the differences in overall survival reported based on historical grading systems, future studies on DMG-SCs are needed to further define if DMG-SCs may represent a heterogeneous group of tumors with different prognoses.
引用
- Watanabe G, Wong JM, Estes B, et al. Diffuse Midline H3K27-Altered Gliomas in the Spinal Cord: A Systematic Review. J Neurooncol. 2024. PMID: 38342826. doi:10.1007/s11060-024-04584-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。